-
公开(公告)号：US20210023196A1
公开(公告)日：2021-01-28
申请号：US16995439
申请日：2020-08-17
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , A61K39/12 , C07K16/10 , A61K39/13 , A61K39/39
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US20200000908A1
公开(公告)日：2020-01-02
申请号：US16265681
申请日：2019-02-01
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , A61K39/12 , C07K16/10 , A61K39/13 , A61K39/39
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US11633468B2
公开(公告)日：2023-04-25
申请号：US16995439
申请日：2020-08-17
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US20210220465A1
公开(公告)日：2021-07-22
申请号：US17224430
申请日：2021-04-07
申请人： Vactech Oy
发明人： Heikki Hyöty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , A61K39/12 , C07K16/10 , A61K39/13 , A61K39/39
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US10780157B2
公开(公告)日：2020-09-22
申请号：US16265681
申请日：2019-02-01
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US10258685B2
公开(公告)日：2019-04-16
申请号：US15465854
申请日：2017-03-22
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US11911456B2
公开(公告)日：2024-02-27
申请号：US17224430
申请日：2021-04-07
申请人： Vactech Oy
发明人： Heikki Hyöty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
CPC分类号： A61K39/125 , A61K39/12 , A61K39/13 , A61K39/39 , C07K16/1009 , A61K2039/505 , A61K2039/5252 , A61K2039/5258 , A61K2039/53 , A61K2039/55 , A61K2039/58 , C12N2770/32334
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US10675344B2
公开(公告)日：2020-06-09
申请号：US16265677
申请日：2019-02-01
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US20190209675A1
公开(公告)日：2019-07-11
申请号：US16265677
申请日：2019-02-01
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , C07K16/10 , A61K39/12 , A61K39/39 , A61K39/13
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US20170281748A1
公开(公告)日：2017-10-05
申请号：US15465854
申请日：2017-03-22
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , A61K39/39 , A61K39/13 , A61K39/12 , C07K16/10
CPC分类号： A61K39/125 , A61K39/12 , A61K39/13 , A61K39/39 , A61K2039/505 , A61K2039/5252 , A61K2039/5258 , A61K2039/53 , A61K2039/55 , A61K2039/58 , C07K16/1009 , C12N2770/32334
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.015 秒)
